FRAMEWORK-CRC
Fruquintinib Real-World Outcomes in mCRC – A Prospective
Study of One-Year Progression-Free Survival and Overall
Survival in Polish Patients.
Study of One-Year Progression-Free Survival and Overall
Survival in Polish Patients.
Dear Sir or Madam,
we would like to invite you to participate in a multicenter, prospective observational study of metastatic colorectal cancer.
The registration and login panel for the eCRF system is available on the right.
Study Sponsor:
Takeda Pharma sp. z o.o.
ul. Prosta 28, 00-838 Warsaw, Poland
ul. Prosta 28, 00-838 Warsaw, Poland
Clinical Research Organization:
(contracted by the Sponsor)
Biostat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik, Poland
ul. Kowalczyka 17, 44-206 Rybnik, Poland
phone: +48 530 714 118
e-mail: [email protected]
e-mail: [email protected]
VV-MEDMAT-137808, 06/2026
2026 Takeda Pharmaceutical Company Limited. All rights reserved.
Content is protected by copyright and may not be copied, modified, or distributed without prior written permission, except for limited non-commercial use with proper notice.
Content is protected by copyright and may not be copied, modified, or distributed without prior written permission, except for limited non-commercial use with proper notice.
Please log in using the details provided after signing the agreement.